Internal Medicine, Infectious Disease · Jacksonville, FL
NPI
1326016536
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
6817 Southpoint Pkwy Ste 802
Jacksonville, FL, 32216
Phone (904) 646-1987
Groups this clinician bills Medicare through
Medicare paid, 2024
$93K
1,192 services
Medicare patients, 2024
404
Average age 75
Drug cost, 2024
$5.1M
1,940 prescriptions
Company payments, 2025
$1,731
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ivan A Guerrero was code 99232 (hospital e&m - subsequent), 709 times for 266 patients. In total Ivan A Guerrero billed 1,192 services in 11 codes, and Medicare paid $93K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-07-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 709 | 266 | $61.25 | $43K |
| 99222 Hospital E&M - Initial | Facility | 228 | 215 | $101.81 | $23K |
| 99214 Office E&M - Established | Office | 134 | 80 | $91.46 | $12K |
| 99223 Hospital E&M - Initial | Facility | 65 | 61 | $135.01 | $8,775 |
| 99204 Office E&M - New | Office | 21 | 21 | $130.01 | $2,730 |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 11 | 11 | $41.11 | $452 |
By year: 2022 $99K for 1,197 services; 2023 $100K for 1,208 services; 2024 $93K for 1,192 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ivan A Guerrero prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 387 prescriptions and refills. In total Ivan A Guerrero wrote 1,940 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 387 | 405 | 40 | $1.5M |
| Juluca Dolutegravir/Rilpivirine | 159 | 159 | 15 | $516K |
| Dovato Dolutegravir Sodium/Lamivudine | 133 | 133 | 14 | $387K |
| Tivicay Dolutegravir Sodium | 116 | 116 | 15 | $252K |
| Prezcobix Darunavir/Cobicistat | 89 | 89 | Under 11 | $207K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 86 | 86 | Under 11 | $344K |
| Rukobia Fostemsavir Tromethamine | 70 | 80 | Under 11 | $689K |
| Descovy Emtricitabine/Tenofov Alafenam | 62 | 62 | Under 11 | $130K |
| Etravirine Generic | 53 | 53 | Under 11 | $53K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 47 | 49 | Under 11 | $233K |
| Ceftriaxone Ceftriaxone Sodium | 46 | 46 | 14 | $1,993 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 46 | 70 | Under 11 | $252K |
| Doxycycline Hyclate Generic | 41 | 41 | 11 | $384 |
| Emtricitabine-Tenofovir Disop Emtricitabine/Tenofovir (Tdf) | 33 | 33 | Under 11 | $2,424 |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 32 | 32 | Under 11 | $113K |
Brand drugs: 1,332 claims; generic drugs: 608 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ivan A Guerrero $1,731 ($1,731 in general payments such as food, travel and fees) from 9 companies. The largest payer was ViiV Healthcare Company with $582.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 24 | $582 |
| Gilead Sciences, Inc. GILD | 19 | $477 |
| Merck Sharp & Dohme LLC MRK | 11 | $283 |
| Paratek Pharmaceuticals, Inc. | 5 | $123 |
| Theratechnologies Inc. THTX | 3 | $87.54 |
| Napo Pharmaceuticals Inc | 4 | $72.52 |
| Aimmune Therapeutics, Inc. | 3 | $65.84 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $23.99 |
| Insmed, Inc. INSM | 1 | $16.9 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.